WASHINGTON — In a move aimed at fulfilling a long-standing promise, President Donald Trump announced a landmark agreement with pharmaceutical giant Pfizer on Tuesday, a deal designed to significantly lower prescription drug costs for Americans and boost domestic manufacturing.
The agreement, unveiled at the White House, centers on two key initiatives. First, it implements a “Most Favored Nation” pricing model for Medicaid, which will align U.S. drug costs with the lowest prices paid by other developed nations. Second, it launches the new “TrumpRx” website, which will offer the public discounts of 50% to 100% on a selection of Pfizer medications.
“This is a great deal for the American people,” President Trump stated during the announcement.
Beyond the immediate price reductions, Pfizer has committed to investing $70 billion in U.S. manufacturing and research and development over the coming years, a provision touted to strengthen the domestic pharmaceutical industry and create jobs.
The initiative received strong endorsement from Health and Human Services Secretary Robert F. Kennedy Jr., who praised it as a “long-sought achievement” in the effort to make medicine more affordable.
However, the deal was met with criticism from some vaccine skeptics, who questioned President Trump’s endorsement of Pfizer CEO Albert Bourla. The criticism highlights the ongoing political debates surrounding COVID-19 vaccines, a product for which Pfizer is a leading manufacturer.
